CordenPharma Colorado logo

CordenPharma Colorado

USA (Boulder, CO) • CDMO

CordenPharma Colorado is a peptide CDMO based in USA (Boulder, CO). Direct manufacturer. Founded 2011. Holds US DMFs for linaclotide API.

ConfidenceHigh
Business TypeCDMO
ModelManufacturer
RegionNorth America
Founded2011
Verification status based on publicly available information and supplier-provided materials.

Listing reviewed September 2026.

Is this your company? Claim this listing to update your info and get a verified badge.Claim This Listing

Global CDMO operating the world's largest Solid-Phase Peptide Synthesis (SPPS) plant in Boulder, CO. cGMP-certified, FDA-inspected facility. 10,000L SPPS reactors with >2 metric tons annual capacity. Full lifecycle peptide API services from process development through commercial ton-scale production. €900M expansion underway (2024-2028) to more than double capacity. Also operates a second Boulder site for HPAPIs acquired from Pfizer/Hospira. Part of CordenPharma Group (Astorg portfolio).

Directory assessment: CordenPharma Colorado is listed as a CDMO in the peptide supply chain, serving North America markets from USA (Boulder, CO). As a direct manufacturer, this supplier controls its own production process from synthesis through purification and quality control release testing. This profile lists 3 sources for reference. This supplier has a strong confidence score, indicating a high level of verification and reliability for B2B sourcing.

Products (6)
Peptide APIsCustom Peptide SynthesisProcess DevelopmentHPAPIsOligonucleotidesLipids
US Drug Master Files
  • Linaclotide: DMF 24992 (Type II, active), submitted 2011-05-27

DMF numbers from the FDA quarterly DMF list. A filed DMF is not FDA approval; its contents are confidential. Reviewed 2026-10-23.